| Date | Title | Description |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 13.01.2025 | Windward Bio: Drug Development Company Raises $200 Million (Series A) | Novo Holdings, a leading life science investor, announced that it has invested in a $200 million Series A launch financing for Windward Bio. This oversubscribed financing was co-led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportu... |
| 11.01.2025 | A New Dawn in Immunotherapy: Harbour BioMed and Kelun-Biotech's Strategic Move with Windward Bio | In the fast-paced world of biopharmaceuticals, partnerships can be the lifeblood of innovation. The recent collaboration between Harbour BioMed, Kelun-Biotech, and Windward Bio marks a significant milestone in the development of immunologic... |
| 11.01.2025 | Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb). | CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "... |
| 10.01.2025 | Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD | Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IN... |
| 10.01.2025 | Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of ... |
| - | Windward Bio | “Windward Bio” |